pyrroles has been researched along with paclitaxel in 67 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.99) | 18.2507 |
| 2000's | 23 (34.33) | 29.6817 |
| 2010's | 35 (52.24) | 24.3611 |
| 2020's | 7 (10.45) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, I; Aristoff, PA; Laborde, AL; Sampson, KE; Shelly, JA; Skulnick, HI; Wolf, CL | 1 |
| Abraham, I; Olsen, MK; Reszka, AA | 1 |
| Edatsugi, H; Matsuba, Y; Matsunaga, A; Mita, I; Nakanishi, O | 1 |
| Brandt, R; Hynes, NE; Wong, AM | 1 |
| Berger, NA; Berger, SJ; Dowlati, A; Gerson, SL; Haaga, J; Liu, L; Remick, SC; Spiro, TP; Willson, JK | 1 |
| Baker, CH; Bucana, CD; Fidler, IJ; Kedar, D; McCarty, MF; Tsan, R; Weber, KL | 1 |
| Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Shepherd, DL; Uehara, H | 1 |
| Larsson, C; Svensson, K | 1 |
| Baker, C; Doucet, M; Fidler, IJ; Kim, SJ; Price, JE; Weber, KL | 1 |
| Ledbetter, S; Pratt, BM; Teicher, BA; Walter-Yohrling, J | 1 |
| Bekele, BN; Bucana, CD; Doan, DD; Fidler, IJ; Greenberg, JS; Holsinger, FC; Jasser, SA; Myers, JN; Schiff, BA; Swan, EA; Younes, MN | 1 |
| Caniatti, M; Cherrington, JM; Colombo, T; Garofalo, A; Ghilardi, C; Ghisleni, G; Giavazzi, R; Manenti, L; Naumova, E; Nicoletti, MI; Scanziani, E | 1 |
| Doucet, M; Price, JE; Weber, KL | 1 |
| Fan, D; Fidler, IJ; He, J; Killion, JJ; Kim, SJ; Langley, RR; Tsan, R; Uehara, H; Yazici, S | 1 |
| Cooney, MM; Dowlati, A; Hoppel, CL; Ingalls, ST; Ivy, P; Ksenich, P; Lavertu, P; Makar, V; McCrae, K; McPeak, RJ; Overmoyer, B; Remick, S; Tserng, KY | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Kenji, Y; O'reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Bani, MR; Borsotti, P; Cassis, L; Eccles, SA; Garofalo, A; Giavazzi, R; Naumova, E; Riccardi, E; Scanziani, E; Ubezio, P | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Castagliuolo, I; Ferlin, MG; Gasparotto, V | 1 |
| Alagkiozidis, I; Coukos, G; Gimotty, PA; Guo, W; Holtz, DO; Krafty, RT; Leiby, B; Mohamed-Hadley, A; Zhang, L | 1 |
| Albrecht, W; Laufer, S; Nussler, AK; Unger, A | 1 |
| Domb, AJ; Kumar, N; Mandler, D; Nyska, A; Okner, R; Oron, M; Tal, N | 1 |
| Bane, FT; Bannon, JH; Campaini, G; Campiani, G; Mc Gee, MM; Pennington, SR; Williams, DC; Zisterer, DM | 1 |
| Cataruozolo, PE; Chuang, E; Collier, M; Gowland, PA; Huang, X; Kern, KA; Kozloff, M; Miller, K; Starr, A; Verkh, L | 1 |
| Kolb, MM; Kozloff, MF; Samant, M; Scappaticci, FA; Socinski, MA | 1 |
| Díaz-Rubio, E; López-Tarruella, S; Manzano, A; Martin, M; Puente, J | 1 |
| Domb, AJ; Favaro, G; Mandler, D; Okner, R; Shaulov, Y; Tal, N | 1 |
| Arias-Pulido, H; Brouwer-Visser, J; Goldberg, GL; Hebert, TM; Horwitz, SB; Huang, GS; Kim, CH; Lin, J; Prossnitz, ER; Qualls, CR; Ramirez, MJ; Smith, HO | 1 |
| Burstein, HJ; Dhakil, S; Fabian, C; Kozloff, M; Mayer, EL; Parmar, H; Patel, T; Qamar, R; Samant, M; Sundaram, S; Volterra, F | 1 |
| Chow, LM; Jiang, T; Wan, SB; Wong, IL; Yan, CS; Zhang, PY; Zhang, XY | 1 |
| Aohara, F; Fujimura, Y; Harakawa, N; Hasegawa, R; Katori, N; Kim, SR; Maekawa, K; Naito, M; Niwa, T; Okuda, H; Sai, K; Saito, Y; Sawada, J; Tohkin, M; Yoshimura, T | 1 |
| Blumenschein, GR; Chao, RC; Cohen, RB; Heath, EI; Kim, ST; Loconte, NK; Lorusso, PM; Ruiz-Garcia, A; Wilding, G | 1 |
| Brufsky, AM; Copur, MS; Davis, J; Generali, D; Gernhardt, D; Giguere, JK; Gressot, L; Huang, X; Kern, KA; Liau, KF; Minton, SE; Paul, D; Richards, PD; Robert, NJ; Saleh, MN; Smith, JW | 1 |
| Bogatcheva, NV; Daglis, GA; Gorshkov, BA; Kim, KM; Poirier, C; Verin, AD; Zemskova, MA | 1 |
| Albain, KS; Besse, B; Blais, N; Chao, RC; Gervais, R; Hainsworth, JD; Hamm, JT; Kim, ST; Laskin, J; Lipton, A; Masters, GA; Natale, RB; Page, RD; Selaru, P | 1 |
| Chen, Y; Wang, ZJ; Yang, C | 1 |
| Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H | 1 |
| Benemei, S; Creminon, C; Fusi, C; Geppetti, P; Materazzi, S; Nassini, R; Nilius, B; Patacchini, R; Pedretti, P; Prenen, J | 1 |
| Ansari, R; Fisher, W; Hanna, N; Koneru, K; Liu, Z; McClean, J; Robin, E; Schmitt, JM; Sommers, SR; Tong, Y | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Carmeliet, P; Daniels, A; Dhondt, J; Lambrechts, D; Meert, T; Nuydens, R; Peeraer, E; Pintelon, I; Poesen, K; Timmermans, JP; Verheyen, A | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Abe, S; Araki, T; Fushimi, A; Higaki, K; Ishikawa, K; Kimura, T; Molema, G; Ogawara, K; Yoshizawa, Y | 1 |
| Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M | 1 |
| Adjei, AA; Belani, CP; Chow, LQ; Dy, GK; Fortin, C; Gupta, A; Jonker, DI; Laurie, SA; Nicholas, G; Park, JS; Patricia, D; Sbar, EI; Zhang, S | 1 |
| Chello, M; Coccia, R; Covino, E; De Marco, F; Di Domenico, F; Di Sciascio, G; Lusini, M; Patti, G; Pettinari, M; Pollari, F; Spadaccio, C; Zanzonico, R | 1 |
| Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Li, J; Shi, Y; Xing, P | 1 |
| Bonanno, G; Di Cesare Mannelli, L; Fariello, RG; Farina, C; Ghelardini, C; Milanese, M; Misiano, P; Pittaluga, A | 1 |
| Hainsworth, JD; Midha, R; Peacock, NW; Priego, VM; Shastry, M; Shipley, DL; Yardley, DA | 1 |
| Kayser, G; Klement, GL; Rössler, J; Saueressig, U; von Winterfeld, M | 1 |
| Amendola, V; Litti, L; Meneghetti, M; Toffoli, G | 1 |
| Brown-Glaberman, U; Chalasani, P; Iannone, M; Livingston, R; Marron, M; Specht, J; Stopeck, AT | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Xie, Z; Zhang, T; Zhang, W; Zheng, M | 1 |
| Alarcón, E; Armstrong, AC; Cheung, SYA; Corcoran, C; Cullberg, M; Davies, BR; de Bruin, EC; Foxley, A; Gómez Villanueva, A; Lindemann, JPO; López Chuken, YA; Maudsley, R; Moschetta, M; Oliveira, M; Outhwaite, E; Pass, M; Pérez-Fidalgo, JA; Philco, M; Rugman, P; Sablin, MP; Schiavon, G; Tamura, K; Turner, NC | 1 |
| Carr, TH; Citi, V; Cutts, R; de Bruin, EC; Fenwick, K; Garcia-Murillas, I; Hrebien, S; Kozarewa, I; Maudsley, R; McEwen, R; Oliveira, M; Ratnayake, J; Schiavon, G; Turner, N | 1 |
| Adler, S; Aljumaily, R; Antal, JM; Beck, JT; Boccia, RV; Bulat, I; Chiu, VK; Csoszi, T; Domine Gomez, M; Dragnev, KH; Hamm, JT; Hanna, W; Hart, LL; Hoyer, RJ; Hussein, MA; Lai, AY; Lowczak, A; Maglakelidze, M; Malik, RK; Morris, SR; Nikolinakos, P; Owonikoko, TK; Richards, DA; Roberts, PJ; Rocha Lima, CM; Sawrycki, P; Schuster, SR; Sorrentino, JA; Weiss, JM; Yang, Z | 1 |
| Alhudaithi, SS; Almuqbil, RM; Bielski, ER; Bos, PD; da Rocha, SRP; Du, W; Sunbul, FS; Zhang, H | 1 |
| Al-Matarneh, MC; Amărandi, RM; Danac, R; Mangalagiu, II | 1 |
| Lin, Z; Liu, JY; Wang, S; Weng, XL; Yang, DC; Zhang, HX | 1 |
| Cao, AY; Chai, WJ; Chen, CM; Chen, L; Chen, X; Di, GH; Fan, L; Guo, X; Hou, YF; Hu, X; Hu, Z; Huang, XY; Jiang, YZ; Li, JJ; Liu, GY; Ma, XY; Shao, ZM; Sun, XJ; Wang, ZH; Wu, J; Wu, SY; Xu, Y; Yang, WT; Yu, KD; Zhao, S; Zhu, XY; Zou, JJ | 1 |
| Andrikopoulou, A; Chatzinikolaou, S; Dimopoulos, MA; Kaparelou, M; Liontos, M; Panourgias, E; Zagouri, F | 1 |
| Loi, S; Salgado, R | 1 |
| Bikinieva, F; Boichuk, S; Galembikova, A; Mustafin, I; Ryzkin, S; Zykova, S | 1 |
5 review(s) available for pyrroles and paclitaxel
| Article | Year |
|---|---|
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Personalized Therapy for Generalized Lymphatic Anomaly/Gorham-Stout Disease With a Combination of Sunitinib and Taxol.
Topics: Administration, Metronomic; Adolescent; Child; Chronic Pain; Combined Modality Therapy; Dietary Fats; Drug Synergism; Drug Therapy, Combination; Fatal Outcome; Humans; Indoles; Lymphatic Abnormalities; Male; Osteolysis, Essential; Paclitaxel; Pelvic Bones; Pleural Effusion; Precision Medicine; Pyrroles; Radiography; Recurrence; Remission Induction; Respiration, Artificial; Respiratory Insufficiency; Sunitinib; Triglycerides | 2015 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
"The emerging role of capivasertib in breast cancer".
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2022 |
13 trial(s) available for pyrroles and paclitaxel
| Article | Year |
|---|---|
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Head and Neck Neoplasms; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles | 2005 |
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate | 2010 |
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Endpoint Determination; Female; Half-Life; Hematologic Diseases; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Indoles; Male; Middle Aged; Paclitaxel; Pyrroles; Sunitinib | 2012 |
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperidines; Pyrroles; Treatment Outcome; Triazines | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Estrogen; Survival Rate | 2019 |
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Paclitaxel; Prognosis; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma; Survival Rate; Tissue Distribution | 2019 |
49 other study(ies) available for pyrroles and paclitaxel
| Article | Year |
|---|---|
K252a, KT5720, KT5926, and U98017 support paclitaxel (taxol)-dependent cells and synergize with paclitaxel.
Topics: Alkaloids; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbazoles; Cell Division; Cell Line; CHO Cells; Cricetinae; Drug Synergism; Indole Alkaloids; Indoles; Myosin-Light-Chain Kinase; Paclitaxel; Pyrroles; Staurosporine | 1994 |
KT5720 and U-98017 inhibit MAPK and alter the cytoskeleton and cell morphology.
Topics: Animals; Antibodies; Antineoplastic Agents, Phytogenic; Calcium-Calmodulin-Dependent Protein Kinases; Carbazoles; Cell Size; CHO Cells; Cricetinae; Cytoskeleton; Enzyme Inhibitors; Fluorescent Antibody Technique, Indirect; Indoles; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; Protein Kinases; Pyrroles; Staurosporine; Tubulin | 1998 |
A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Benzimidazoles; Cell Survival; Cisplatin; Colonic Neoplasms; DNA; Female; Fluorescent Dyes; Humans; Leukemia L1210; Leukemia P388; Macromolecular Substances; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Paclitaxel; Pyrroles; Radiation-Sensitizing Agents | 2000 |
Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Genes, erbB-2; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Paclitaxel; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2001 |
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
Topics: Animals; Antineoplastic Agents; Biopsy; Carmustine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Fenretinide; Guanine; Humans; Indoles; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Pyrroles; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2002 |
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Bone and Bones; Bone Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; ErbB Receptors; Fibroblast Growth Factor 2; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
A protein kinase Cbeta inhibitor attenuates multidrug resistance of neuroblastoma cells.
Topics: Carboplatin; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Maleimides; Mesylates; Neuroblastoma; Paclitaxel; Peripheral Nervous System Neoplasms; Protein Kinase C; Pyrroles; Tumor Cells, Cultured; Vincristine | 2003 |
Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Division; Epidermal Growth Factor; ErbB Receptors; Humans; Kidney Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Recombinant Proteins; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Fibroblasts; Humans; Immunohistochemistry; Indoles; Metalloproteases; Neoplasm Invasiveness; Neoplasms; Oxindoles; Paclitaxel; Propionates; Protease Inhibitors; Pyrroles; Stromal Cells | 2003 |
Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Ligands; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Mouth Neoplasms; Neoplasms; Paclitaxel; Phosphorylation; Propidium; Pyrimidines; Pyrroles; Tongue; Tongue Neoplasms; Tyrosine | 2003 |
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Oxindoles; Paclitaxel; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Renal Cell; ErbB Receptors; Kidney Neoplasms; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Tumor Cells, Cultured | 2003 |
Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Substrate Specificity; Xenograft Model Antitumor Assays | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Animal; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Survival Rate | 2004 |
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line; Cell Line, Tumor; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Female; Immunohistochemistry; Indoles; Laminin; Mice; Mice, Nude; Myocytes, Smooth Muscle; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxindoles; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Protein-Tyrosine Kinases; Proteoglycans; Pyrroles; Xenograft Model Antitumor Assays | 2006 |
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Paclitaxel; Pyrroles; Quinolones; Structure-Activity Relationship | 2007 |
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoles; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Microcirculation; Ovarian Neoplasms; Paclitaxel; Pyrroles; Recombinant Proteins; Vascular Endothelial Growth Factor A | 2008 |
In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase.
Topics: Acetates; Animals; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cyclopropanes; Cytochrome P-450 Enzyme System; Glucuronosyltransferase; Hepatocytes; Humans; Lipoxygenase Inhibitors; Macaca fascicularis; Mice; Mice, Inbred Strains; Microsomes; Paclitaxel; Pyrroles; Quinolines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfides | 2008 |
Electrocoating of stainless steel coronary stents for extended release of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Drug Delivery Systems; Electrochemistry; Esters; Female; Materials Testing; Mice; Molecular Structure; Paclitaxel; Polymers; Pyrroles; Stainless Steel; Stents; Surface Properties | 2009 |
The microtubule-targeting agents, PBOX-6 [pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and pin1,
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Division; Cell Membrane; Cell Nucleus; Cyclophilin A; Cytoplasm; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; G2 Phase; Hematologic Neoplasms; Humans; Hydrolysis; Microtubules; Monocytes; NIMA-Interacting Peptidylprolyl Isomerase; Oxazepines; Paclitaxel; Peptide Mapping; Peptidylprolyl Isomerase; Pyrroles; Silver Staining; Trypsin | 2009 |
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Hypothyroidism; Indoles; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pyrroles; Remission Induction; Sunitinib; Trastuzumab | 2010 |
Electropolymerized tricopolymer based on N-pyrrole derivatives as a primer coating for improving the performance of a drug-eluting stent.
Topics: Absorption; Blood Vessel Prosthesis; Coated Materials, Biocompatible; Drug-Eluting Stents; Electrochemistry; Equipment Design; Equipment Failure Analysis; Hardness; Materials Testing; Paclitaxel; Polymers; Pyrroles; Surface Properties | 2009 |
Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor II; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA, Small Interfering; Signal Transduction | 2010 |
Design and syntheses of permethyl ningalin B analogues: potent multidrug resistance (MDR) reversal agents of cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Doxorubicin; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Paclitaxel; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Vincristine | 2010 |
CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.
Topics: Alleles; Animals; Asia, Eastern; Atorvastatin; Biocatalysis; Camptothecin; Carbamazepine; Cytochrome P-450 CYP3A; Docetaxel; Heptanoic Acids; Humans; Irinotecan; Midazolam; Models, Molecular; Paclitaxel; Pyrroles; Spodoptera; Substrate Specificity; Taxoids; Terfenadine | 2010 |
Ezrin, radixin, and moesin are phosphorylated in response to 2-methoxyestradiol and modulate endothelial hyperpermeability.
Topics: 2-Methoxyestradiol; Animals; Capillary Permeability; Cells, Cultured; Cytoskeletal Proteins; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Estradiol; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Indoles; Male; Maleimides; Membrane Proteins; Mice; Microfilament Proteins; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Protein Kinase C; Pyrroles; rho-Associated Kinases; Tubulin Modulators | 2011 |
Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain.
Topics: Analysis of Variance; Anilides; Animals; Ankyrins; Antineoplastic Agents, Phytogenic; Capsaicin; Carbazoles; Central Nervous System; Cinnamates; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Estrenes; Gene Expression Regulation; Hyperalgesia; Male; Mice; Mice, Inbred ICR; Neuralgia; Oligopeptides; Paclitaxel; Pain Measurement; Physical Stimulation; Protein Kinase C; Pyrroles; Pyrrolidinones; Receptor, PAR-2; Sulfonamides; Time Factors; TRPV Cation Channels; Tryptases; Type C Phospholipases | 2011 |
TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism.
Topics: Acetanilides; Animals; Calcitonin Gene-Related Peptide; Capsaicin; Cold Temperature; Drug Hypersensitivity; Glutathione; Hyperalgesia; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Paclitaxel; Peripheral Nervous System Diseases; Purines; Pyrroles; Transient Receptor Potential Channels; TRPA1 Cation Channel; TRPV Cation Channels | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy.
Topics: Animals; Antibodies, Neutralizing; Behavior, Animal; Ganglia, Spinal; Indoles; Mice; Mice, Transgenic; Neuralgia; Neurons; Paclitaxel; Pain Measurement; Polyneuropathies; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Humans; Immunoenzyme Techniques; Indoles; Liposomes; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Pericytes; Polyethylene Glycols; Pyrroles; Solubility; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Mice; Mice, Nude; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Rabeprazole; Random Allocation; Sunitinib; Triazines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study).
Topics: Aged; Angina, Stable; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Restenosis; Diabetes Complications; Drug-Eluting Stents; Female; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; ROC Curve; Tubulin Modulators | 2013 |
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan | 2013 |
[Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2013 |
Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain.
Topics: Analysis of Variance; Animals; Anti-Retroviral Agents; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Hyperalgesia; Imidazoles; Male; Neuralgia; Osteoarthritis, Knee; Paclitaxel; Pain Measurement; Pain Threshold; Physical Stimulation; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Vincristine; Weight-Bearing | 2014 |
Detection of low-quantity anticancer drugs by surface-enhanced Raman scattering.
Topics: Antineoplastic Agents; Camptothecin; Doxorubicin; Humans; Indoles; Irinotecan; Limit of Detection; Paclitaxel; Pyrroles; Spectrum Analysis, Raman; Sunitinib; Surface Properties | 2016 |
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Cyclophosphamide; Doxorubicin; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib | 2016 |
Near-infrared BODIPY-paclitaxel conjugates assembling organic nanoparticles for chemotherapy and bioimaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Boron Compounds; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Fluorescent Dyes; Halogenation; Humans; Infrared Rays; Mice; Mice, Inbred Strains; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Paclitaxel; Particle Size; Pyrroles; Surface Properties; Tumor Cells, Cultured | 2018 |
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2019 |
Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
Topics: Administration, Inhalation; Administration, Intravenous; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Paclitaxel; Phosphorylation; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tumor Microenvironment; Tumor-Associated Macrophages | 2020 |
Synthesis and Biological Screening of New Cyano-Substituted Pyrrole Fused (Iso)Quinoline Derivatives.
Topics: Benzophenones; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Isoquinolines; Microtubules; Molecular Docking Simulation; Nitriles; Paclitaxel; Protons; Pyrroles | 2021 |
Singlet Oxygen-Responsive Polymeric Nanomedicine for Light-Controlled Drug Release and Image-Guided Photodynamic-Chemo Combination Therapy.
Topics: Acrylates; Animals; Antineoplastic Agents; Boron Compounds; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; Humans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polyesters; Polyethylene Glycols; Pyrroles; Singlet Oxygen | 2021 |
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Humans; Indoles; Paclitaxel; Pyrroles; Triple Negative Breast Neoplasms | 2022 |
What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Indoles; Paclitaxel; Pyrroles; Triple Negative Breast Neoplasms | 2022 |
2-Amino-Pyrrole-Carboxylate Attenuates Homology-Mediated DNA Repair and Sensitizes Cancer Cells to Doxorubicin.
Topics: Antineoplastic Agents; DNA Damage; DNA Repair; Doxorubicin; Humans; Neoplasms; Paclitaxel; Pyrroles | 2022 |